latest news

Press releases

Adela Appoints Precision Medicine Veteran Lisa Alderson as CEO

December 14, 2023

Ms. Alderson is a seasoned healthcare CEO who brings over 20 years of experience building early-stage companies at the intersection of technology and healthcare

Adela Presents Data Demonstrating Strong Prognostic Prediction Capabilities in Lung Cancer at the 2023 Multidisciplinary Thoracic Cancers Symposium

November 30, 2023

Individuals with higher quantities of cancer signal from cell-free DNA (cfDNA) prior to treatment had a significantly increased likelihood of recurrence post-treatmentAdela’s tissue-agnostic platform shows potential to inform treatment decisions by predicting prognosis

Adela Presents Data Demonstrating Strong Prognostic Prediction Capabilities in Head and Neck Cancer and Renal Cell Carcinoma at the ESMO 2023 Congress

October 19, 2023

Individuals with higher quantities of circulating tumor DNA (ctDNA) prior to treatment had a significantly increased likelihood of recurrence or progression. Adela’s tissue-agnostic platform shows potential to inform treatment decisions by predicting prognosis.

Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach

September 25, 2023

Investors include F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, Labcorp and RA Capital Management. Proceeds from this financing will be used to advance Adela’s technology platform and commercialize Adela’s first product for MRD monitoring, while further developing a multi-cancer early detection (MCED) product. Lisa Alderson – seasoned CEO and healthcare innovator - appointed as Interim CEO of Adela.

Adela Announces Appointment of Alan Williams as Chief Operating Officer

May 11, 2023

A life sciences veteran who has led organizations through the successful development, launch and scale-up of multiple, first-in class products.

Adela presents data demonstrating strong detection of 12 cancer types at the American Association for Cancer Research Annual Meeting 2023

April 16, 2023

Adela’s platform demonstrated strong detection for early stage cancers

Adela to present data demonstrating detection of multiple cancer types at the American Association for Cancer Research Annual Meeting 2023

March 15, 2023

Adela, Inc. announced today that it will present data demonstrating the ability of its genome-wide methylome enrichment platform to detect multiple types of cancer at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023.

Adela’s Co-Founder & Chief Scientific Officer to Deliver Plenary Session at American Association for Cancer Research (AACR) Special Conference on Precision Prevention, Early Detection, and Interception of Cancer

November 15, 2022

Daniel De Carvalho, PhD will deliver a plenary session titled “Cancer Early Detection, Classification and Monitoring using Plasma Cell-Free DNA Methylomes” at the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer on November 18, 2022.

Adela Initiates Key Study for Cancer Early Detection Program

May 25, 2022

Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has enrolled the first participant in a multi-center study supporting the development and validation of its genome-wide methylome enrichment platform for the early detection of cancer.

Adela Announces Executive and Board of Directors Appointments and Formation of Scientific Advisory Board

May 23, 2022

Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has made appointments to the Executive Team and Board of Directors that add to the deep industry and scientific expertise of the current team. The company has also formed a Scientific Advisory Board comprised of renowned scientists and clinicians. 

Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer and Other Diseases

June 23, 2021

Adela’s technology detects signals of early disease with high sensitivity through efficient mining of the entire methylome